+91-8668442535
Home / Biotechnology / Hospital A

Hospital Acquired Disease Testing Market by Infection Type (Pneumonia, Urinary Tract Infection, Blood Stream Infection, Surgical Site Infection, MRSA) - Growth, Share, Opportunities & Competitive Analysis, 2015 - 2022

Hospital-acquired infections (HAI) or diseases, also called nosocomial infections, are acquired in healthcare in-patient settings. It is estimated that in the U.S., 9.2 out of every 100 parents acquire hospital infections. Urinary tract infection and pneumonia are the most common types of HAI, followed by bloodstream infection and surgical site infection. These infections are caused by pathogens among patients with compromised immunity. Patients may also develop HAIs due to sub-standard healthcare settings and negligence on the part of hospital staff. The mortality and morbidity of HAIs and the associated costs have urged caregivers to devise efficient infection control strategies. An accurate and in-time diagnosis of HAIs is vital for efficient control and management of HAI.

The global hospital acquired disease testing market report studies this market in terms of major types of HAIs. These include hospital-acquired pneumonia, urinary tract infection, bloodstream infection, surgical site infection, Methicillin-resistant Staphylococcus aureus (MRSA), and others. This report studies these segments in terms of their historical and future market size and forecast for the period 2014-2022. Respective compounded annual growth rates (CAGR %) for these segments for the period 2016-2022 are also presented in this study.

Geographically, the global hospital-acquired disease testing market is studied for the following regional markets:

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Rest of Asia-Pacific
  • Middle East and Africa
  • Latin America

The market size and forecast for the period 2014-2022, along with the CAGRs for the period 2016-2022, are also provided in this report.

Qualitative information such as drivers, challenges, and future prospects for the global hospital-acquired disease testing market are included in this report. Competition assessment tools such as fractal map analysis and attractive investment proposition are presented in this study to scrutinize competition in the global hospital-acquired disease testing market. This study concludes with a company profiles section that highlights information about the key companies engaged in the development, manufacture, and provision of hospital-acquired disease testing products.

Based on infection types, the global hospital-acquired disease testing market is categorized into:

  • Pneumonia
  • Urinary tract infection
  • Bloodstream infection
  • Surgical site infection
  • MRSA
  • Others

Pneumonia and urinary tract infections are the most common hospital-acquired infections and the largest market segments in 2015. Nosocomial pneumonia, healthcare-associated pneumonia, and ventilator-associated pneumonia are the chief causes of mortality and morbidity in hospital settings. Surgical site infection is the third most common nosocomial infection and involves the skin, muscle, and subcutaneous tissue. The attributable mortality of bloodstream infection is 20%, thus making this segment among the deadliest conditions and thus the most addressable.

Based on geographical segmentation, the global hospital-acquired disease testing market is studied for:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

The regional classification is further elucidated as follows:

  • North America (U.S. & Canada)
  • Europe (U.K., Germany, and Rest of Europe)
  • Asia-Pacific (Japan, China, and Rest of Asia-Pacific)
  • Middle East and Africa
  • Latin America

North America is the largest market for hospital-acquired disease testing due to the multitude of hospital admissions and the growing need for containment of rising morbidity. Stringent guidelines for infection reduction and thus culminating the risk of readmission in hospitals have urged the emerging markets to grow at a rapid CAGR during the forecast period.

Frequently asked questions :

The market for Hospital Acquired Disease Testing Market is expected to reach US$ XX Bn by 2022.

The Hospital Acquired Disease Testing Market is expected to see significant CAGR growth over the coming years, at XX%.

The report is forecasted from 2016-2022.

The base year of this report is 2015.

Becton Dickinson, bioMerieux, Cantel, Cepheid, Diatherix, are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  May 2016
Category:  Biotechnology
Report ID:   57814
Report Format:   PDF
Pages:   120
Rating:    4.3 (55)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support